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A homogeneous HDL-c assay (HDL-H), which uses poly-
ethylene glycol-modified enzymes and sulfated a-cyclo-
dextrin, was assessed for precision, accuracy, and choles-
terol and triglyceride interference. In addition, its
analytical performance was compared with that of a phos-
photungstic acid (PTA)/MgCl2 precipitation method
(HDL-P). Within-run CVs were <1.87%; total CVs were
<3.08%. Accuracy was evaluated in fresh normotriglyceri-
demic sera using the Designated Comparison Method
(HDL-H 5 1.037 Designated Comparison Method 1 4
mg/L; n 5 63) and in moderately hypertriglyceridemic sera
by using the Reference Method (HDL-H 5 1.068 Reference
Method 2 17 mg/L; n 5 41). Mean biases were 4.5% and
2.2%, respectively. In hypertriglyceridemic sera (n 5 85),
HDL-H concentrations were increasingly positively biased
with increasing triglyceride concentrations. The method
comparison between HDL-H and HDL-P yielded the fol-
lowing equation: HDL-H 5 1.037 HDL-P 1 15 mg/L; n 5
478. We conclude that HDL-H amply meets the 1998 NCEP
recommendations for total error; its precision is superior
compared with that of HDL-P, and its average bias re-
mains below 65% as long as triglyceride concentrations
are <10 g/L and in case of moderate hypercholesterolemia.
Several prospective epidemiologic studies and clinical
trials have demonstrated that low concentrations of HDL-
cholesterol (HDL-c)7 are an independent risk factor for
coronary heart disease, the inverse relationship being
maintained over a wide range of HDL-c concentrations
(1, 2). It is estimated that for every 10 mg/L decrease in
HDL-c, the relative risk for coronary disease events in-
creases by 2–3% (3). Also, the relationship appears to be
equally strong in males and females, and among asymp-
tomatic individuals as well as patients with established
coronary disease. High HDL concentrations have been
associated with longevity, whereas some, but not all,
genetic deficiencies of HDL are associated with premature
atherosclerosis (4). Blood HDL-c concentrations are
strongly influenced by family history and certain life-style
factors, such as cigarette smoking, obesity, and physical
inactivity. Frequently, low HDL concentrations are ac-
companied by high concentrations of triglycerides be-
cause of their metabolic interrelationship involving cho-
lesterol ester transfer between HDL particles and
triglyceride-rich lipoproteins (5). Data from the PROCAM
(6) and the Helsinki Heart (7, 8) studies further high-
lighted that the low HDL-c–hypertriglyceridemia syn-
drome is a powerful risk factor for nonfatal myocardial
infarction or coronary artery disease death that would be
overlooked if LDL-cholesterol concentrations alone were
determined. Thus far, no completed clinical trial has been
able to address the efficacy of raising HDL-c alone be-
cause life-style changes and lipid-active agents affect
multiple lipids simultaneously.
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Accordingly, HDL-c determinations are included in
most national coronary heart disease prevention pro-
grams to predict an individual’s risk and to guide treat-
ment (1, 9). As an example, the US National Cholesterol
Education Program (NCEP) Adult Treatment Panel II has
identified an HDL-c concentration ,0.35 g/L as a major
risk factor for coronary heart disease and considers HDL-c
concentrations .0.60 g/L as a negative risk factor (9).
Because of the enhanced role of HDL-c in medical prac-
tice, reliable and easy-to-perform assays are warranted.
Several techniques to determine blood HDL-c have been
described, including ultracentrifugation, high-perfor-
mance liquid chromatography, electrophoresis, and pre-
cipitation-based methods (10). In routine clinical chemis-
try laboratories, HDL-c is frequently measured by means
of chemical precipitation of the apolipoprotein B-contain-
ing lipoproteins with either polyethylene glycol (PEG),
dextran sulfate, or PTA/MgCl2, followed by quantitation
of the cholesterol content in the HDL-containing super-
nate (10). Standardization of these HDL-c assays is chal-
lenging because, in addition to matrix effects, substantial
variability exists between the commonly used precipita-
tion reagents (11–13). In addition, in certain laboratories,
precipitation methods do not meet the imprecision goal
for usefulness of a medical test (14). Finally, precipitation
methods are time-consuming, require relatively large vol-
umes of sample, and are not amenable to full automation.
Recently, a direct assay for HDL-c was developed in
Japan (15) and commercialized by Boehringer. The assay
is based on specific enzymatic hydrolysis of cholesterol
esters and oxidation of cholesterol in HDL particles. The
specificity is achieved by the use of sulfated a-cyclodex-
trin, PEG-modified cholesterol esterases and oxidases,
and by optimization of pH and Mg21 concentration (15).
Determinations can be made directly from serum or
heparin plasma, without any pretreatment of samples. In
this study, we aimed to evaluate this homogeneous
HDL-c assay with respect to accuracy and traceability to
the Reference Methods in two CDC Network Labs. A
major focus was put on the accuracy evaluation in case of
moderate and severe dyslipidemia in comparison with a
conventional chemical precipitation method (PTA/
MgCl2). Furthermore, an extensive precision study was
conducted in one CDC Network Lab. Finally, a field
method comparison between the PTA/MgCl2 precipita-
tion method and the new homogeneous HDL-c method
was performed in five university hospital laboratories.
Materials and Methods
participating laboratories
Accuracy of the homogeneous HDL-c assay was investi-
gated by two European members of the CDC Cholesterol
Reference Method Laboratory Network, i.e., the Rotter-
dam group and the Milan group (16). In Rotterdam, the
CDC HDL-c Reference Method was used, whereas in
Milan, the HDL-c Designated Comparison Method was
performed. Precision and triglyceride interference were
studied extensively in Rotterdam.
Five European university laboratories participated in
the method comparison part of the study (Rotterdam,
Milan, Munich, Freiburg, and Hamburg). In all centers,
uniform protocols and identical lots of reagents, calibra-
tors, and controls were used. Moreover, all centers were
equipped with Hitachi 911 or Hitachi 717 analyzers
(Boehringer Mannheim), and official Boehringer applica-
tions were used.
specimens
Because matrix limitations exist for HDL-c, the mecha-
nism for transferring the accepted accuracy base involves
comparisons using fresh human specimens. To this end,
4 3 6 mL venous whole blood was drawn from fasting
blood donors (n 5 41) and from dyslipidemic outpatients
from the lipid clinic (n 5 85), of whom informed consent
was obtained to establish traceability of the homogeneous
HDL-c assay to the HDL-c Reference Method, whereas
2 3 6 mL whole blood was sufficient for the reference
standardization vs the Designated Comparison Method
(n 5 98 and 35, i.e., from blood donors and outpatients
from the lipid clinic, respectively) (10, 14). Blood was
allowed to clot at room temperature, and serum was
obtained by centrifugation at 1500g during 15 min. Sub-
sequently, specimens were split and handled according to
a standard CDC protocol; one aliquot was stored at 4 °C
and analyzed with the direct HDL-c and PTA/MgCl2-
based method at the day of sample collection, and the
other aliquot was stored at 270 °C for a maximum of 4
weeks until analysis with the Reference Methods took
place.
In the cholesterol interference study (n 5 35), the bias
of both normocholesterolemic (n 5 19) and hypercholes-
terolemic (n 5 16) specimens was checked vs the HDL-c
Designated Comparison Method. All specimens had se-
rum triglycerides ,2 g/L. In the triglyceride interference
study (n 5 85), sera with isolated hypertriglyceridemia
(n 5 32), with isolated hypercholesterolemia (n 5 1), and
with mixed hyperlipidemia (n 5 52) were evaluated vs
the HDL-c Reference Method.
For the method comparison between homogeneous
and precipitation-based HDL-c assays, fresh native sera
from 478 inpatients and outpatients, ;100 sera per center,
that were neither icteric or hemolytic on visual inspection
and had triglycerides ,4 g/L, were collected from the
hospital routine and analyzed. Direct and precipitation-
based HDL-c determinations were performed in each
participating center at the day of blood collection. HDL-c
measurements were performed in singlicate in five inde-
pendent assays.
HDL-c reference method and HDL-c designated
comparison method
Reference points for HDL-c measurements, as recom-
mended by the NCEP Lipoprotein Measurement Working
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group, are: (a) the CDC Reference Method, a three-step
procedure involving ultracentrifugation, precipitation, and
cholesterol analysis; and (b) the CDC Designated Compari-
son Method (DCM) (10, 14, 16). The Reference Method com-
bines removal of VLDL by a b-quantification ultracentrifu-
gation procedure, isolation of HDL by precipitation of LDL
from the b-quantification bottom fraction (d 5 1.006 kg/L)
using 46 mmol/L heparin-Mn21, and cholesterol analysis of
the HDL-c supernate by the CDC-modified Abell-Kendall
Reference Method (17). The DCM involves isolation of HDL
by dextran sulfate-Mg21 precipitation, followed by choles-
terol analysis with the Abell-Kendall method, and requires
normotriglyceridemic sera because of its limited precipita-
tion efficiency (16).
In the multicenter part of the study, HDL-c measure-
ments were performed in five analytical assays; the sera
were analyzed in duplicate with the CDC Reference
Method (n 5 41) and the DCM (n 5 98) and in singlicate
with the homogeneous and precipitation-based HDL-c
method. In the triglyceride interference study (n 5 85),
reference HDL-c analyses were done in duplicate and
routine HDL-c analyses were done in singlicate.
homogeneous HDL-c assay
The reagents for the homogeneous HDL-c assay were
obtained from Boehringer Mannheim. Reagent 1 was
composed of 0.5 mmol/L a-cyclodextrin sulfate, 0.5
g/L dextran sulfate, 2 mmol/L MgCl2, and 0.3 g/L
N-ethyl-N-(3-methyl-phenyl)-N9-succinyl-ethylene dia-
mine in 30 mmol/L 3-(N-morpholino)propane sulfonic
acid buffer, pH 7.0. Reagent 2 contained PEG-coupled
cholesterol esterase ($1 kU/L), PEG-coupled choles-
terol oxidase ($5.6 kU/L), peroxidase (30 kU/L), and
4-aminophenazone (0.5 g/L) in 30 mmol/L 3-(N-mor-
pholino)propane sulfonic acid buffer, pH 7.0. In the
first step, 4 mL of sample was mixed with 300 mL of
reagent 1 and incubated for 5 min at 37 °C. In a second
step, 100 mL of reagent 2 was added and incubated for
an additional 5 min. The resulting color was measured
bichromatically at 600 nm (main wavelength) and 700
nm (subsidiary wavelength).
The first reagent (HDL homogeneous R1, lot 131AEJ,
75 mL) was ready for use. The second reagent was
composed of a lyophilized component (HDL homoge-
neous R2a Lyo, lot 120 AEJ) to be reconstituted with an
aliquot of R2 buffer (HDL homogeneous R2, lot 120 AEJ,
20 mL). After reconstitution, the reagents were kept on
board of the Hitachi analyzers. According to the manu-
facturer, the stability of the reconstituted R2 reagent and
calibration stability is up to 4 weeks at 4–8 °C. For this
study, the reagent was calibrated at the time each assay
was run. For calibration, a human-based calibrator (HDL/
LDL calibrator high, lot ML01 0058) was used, which was
preliminarily “targeted” by the manufacturer using the
PTA/MgCl2 precipitation method (assigned value, 0.704
g/L). The reconstituted calibration material is claimed to
be stable up to 1 day at 4–8 °C.
To assess traceability to the Reference Methods, com-
plete analytical systems should be evaluated (including
instrument model, application, reagent lot, and calibrator
lot). In this reference standardization study, the lot num-
bers displayed above were evaluated; the analyzers used
were a Hitachi 911 in Rotterdam and a Hitachi 717 in
Milan. For precision evaluation, two additional lots of
reagent were investigated on a Hitachi 911 (kit lots were
135AEK and 67241101, respectively). For the bias survey
in dyslipidemic specimens, calibrator lot 19079901 and
reagent lot 68079401 were used.
HDL-c determination by a PTA/MgCl2
precipitation method
The analytical performance of the homogeneous HDL-c
method was compared with the performance of a conven-
tional PTA/MgCl2 precipitation method from the same
manufacturer (Boehringer Mannheim, cat. no. 543003, lot
660393-01). The PTA/MgCl2-based assay was calibrated
with 3.5-fold diluted Calibrator for Automated Systems
(CFAS, Boehringer Mannheim, cat. no. 759350, lot 184927)
in all clinical laboratories, according to the manufacturer’s
instruction (denoted as PTA/MgCl2[CFAS]). To precipi-
tate apolipoprotein B-containing lipoproteins, 200 mL of
serum was mixed with 500 mL of precipitating reagent,
composed of 0.44 mmol/L PTA and 20 mmol/L MgCl2.
The mixture was allowed to stand 5 min and was subse-
quently centrifuged (3000g, 10 minutes, 20 °C). Cholesterol
in HDL was determined with the Boehringer Mannheim
cholesteroloxidase-phenol-aminophenazone (CHOD-PAP)
reagent (cat. no. 1489437, lot 664358-01).
HDL-c determination by a combined
ultracentrifugation and PTA/MgCl2
precipitation method
Laboratories 3 and 4 performed a combined ultracentrif-
ugation and precipitation assay as an additional compar-
ison method. Hitherto, the protocol of the Lipid Research
Clinics Program was followed, with modifications pub-
lished previously (18).
triglyceride assay
Triglycerides were determined with a glycerolphospha-
teoxidase-phenol-aminophenazone method (GPO-PAP)
(Boehringer Mannheim, cat. no. 1058550) on Hitachi 911
or Hitachi 717 analyzers. The application with Selective
Mode Solution (i.e., 200 mmol/L HCl; Boehringer Mann-
heim, cat. no. 1360922) as R2 was used, according to the
manufacturer’s protocol.
analyzers
Homogeneous and precipitation-based HDL-c determina-
tions were performed on Hitachi 911 (n 5 4) or Hitachi
717 (n 5 1) analyzers (Boehringer Mannheim) in each
participating center. Daily maintenance and operation
was performed according to the instructions of the man-
ufacturer.
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control sera
Precision studies were performed by using processed
quality control materials from Boehringer Mannheim:
PrecinormR L (lots 185597 and 186586) and PrecipathR L
neu (lots ML01 0062 and ML02 2716). Besides, several
batches of fresh frozen human sera at three concentrations
(low, medium, and high) were examined.
data analysis
Before starting the multicenter data analysis, it was veri-
fied whether control sera were within the preset control
limits (mean 6 3 SD). In the multicenter part of the study,
1 of 25 homogeneous HDL-c assays had to be omitted (lab
2, first run, n 5 19).
In case of up to 200 paired data points, regression
analyses were performed according to the method of
Passing and Bablok (19); in the case that more than 200
data points had to be compared, orthogonal regression
was used. Total error (%) of the HDL-c assays was
calculated as follows: [(1.96 3 analytical imprecision (%))
1 absolute mean bias (%)] (14). Calculation of mean bias
and total error vs the DCM was, according to CDC recom-
mendations, based solely on specimens with triglycerides
#2 g/L (16). In case of the PTA/MgCl2 precipitation assay,
only data from clear and undiluted supernates, reflecting
complete precipitation of apolipoprotein B-containing li-
poproteins, were included in the final data analysis.
Results
precision
Within-run imprecision data (n 5 21) in processed control
materials are presented in Table 1. Precision evaluation of
the homogeneous HDL-c assay according to NCCLS
EP5-T guidelines (20) was performed in the CDC Net-
work Laboratory of Rotterdam (Table 2). Hitherto, dupli-
cate HDL-c determinations per specimen per assay and
two assays per day for 21 days were analyzed. Between-
run imprecision data, gathered by the participating cen-
ters during the multicenter part of the study and based on
duplicate determinations in lyophilized control materials
and frozen human serum pools, respectively, demonstrate
good precision of the evaluated HDL-c methods at that
time (Tables 3 and 4).
bias vs the cdc ultracentrifugation
reference method
The regression equations of homogeneous precipitation-
based HDL-c method vs the CDC Reference Method are
Table 1. Within-run imprecision data (n 5 21) of the Boehringer homogeneous HDL-c method compared with the Boehringer
PTA/MgCl2 precipitation method.
Laboratory Analyzer
Homogeneous HDL-c methoda PTA-MgCl2 method
a
PNL
lot 186 586
PPL neu
lot ML02 2716
PNL
lot 186 586
PPL neu
lot ML02 2716
Lab 1 Hitachi 911 429 6 5 289 6 3 409 6 4 265 6 4
(1.23%) (1.18%) (1.03%) (1.33%)
Lab 2 Hitachi 717 436 6 5 293 6 3 429 6 7 260 6 4
(1.18%) (1.12%) (1.55%) (1.43%)
Lab 3 Hitachi 911 428 6 4 286 6 1 437 6 6 285 6 3
(0.84%) (0.21%) (1.36%) (1.17%)
Lab 4 Hitachi 911 469 6 3 325 6 2 412 6 7 275 6 6
(0.54%) (0.72%) (1.71%) (2.23%)
Lab 5 Hitachi 911 441 6 3 301 6 2 402 6 3 268 6 1
(0.60%) (0.82%) (0.69%) (0.44%)
The data were produced in a Dutch, an Italian, and three German clinical laboratories (n 5 5) using lyophilized quality control materials.
a Mean 6 SD (mg/L) (CV, %)
Table 2. Precision evaluation of the homogeneous HDL-c assay according to NCCLS EP5-T.
HDL-c lot number
Within-run CV, %a (n 5 21 replicates) Total CV, %a (n 5 21 runs)
Low Medium High Low Medium High
R1: 131AEJ 28.86 6 0.54 42.86 6 0.43 28.89 6 0.63 42.64 6 0.80
R2: 120AEJ (1.87%) (1.00%) (2.18%) (1.88%)
R1/R2: 135AEK 29.15 6 0.34 47.92 6 0.32 85.61 6 0.64 28.53 6 0.69 46.65 6 1.00 83.07 6 1.68
(1.17%) (0.67%) (0.75%) (2.42%) (2.14%) (2.02%)
R1/R2: 67241101 30.42 6 0.21 46.14 6 0.33 69.15 6 0.39 31.12 6 0.96 47.08 6 1.31 70.18 6 1.61
(0.69%) (0.72%) (0.56%) (3.08%) (2.78%) (2.29%)
Three reagent lots were examined. Either lyophilized controls (in combination with lot number 131AEJ for R1 and lot number 120AEJ for R2) or fresh frozen pools
(for kit lot numbers 135AEK, respectively; reagent lot 67241101) at different HDL-c levels were evaluated.
a Mean 6 SD (mg/L) (CV, %).
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presented in Table 5 (HDL-c range, 0.07–0.799 g/L; tri-
glyceride range, 0.44–3.94 g/L). For the homogeneous
HDL-c method (Y) vs the CDC Reference Method (X) the
slope of the regression equation is significantly higher
than one at a 5 0.05, whereas the intercept is not
significantly different from zero. Fig. 1, A and B, demon-
strates a mean bias of 2.2% for the homogeneous HDL-c
method and 23.9% for the PTA/MgCl2 assay, respec-
tively. Assuming that the overall imprecision of the
homogeneous HDL-c assay is maximally 3.08% (Table 2),
the total error of the assay is 8.2%.
bias vs the designated comparison method
The regression equations of homogeneous precipita-
tion-based HDL-c assays vs the DCM are presented in
Table 5 (HDL-c range, 0.186 –1.052 g/L; triglycerides,
#2 g/L; n 5 63). Analogously, the slope of the regres-
sion equation for the homogeneous HDL-c method (Y)
vs the CDC DCM (X) is significantly higher than one at
a 5 0.05. Fig. 1, C and D, demonstrates a mean bias of
4.5% for the homogeneous HDL-c method and 25.0%
for the PTA/MgCl2 assay, respectively. Assuming an
overall imprecision of maximally 3.08% (Table 2) for the
homogeneous assay, the total error of the method is
10.5%.
method comparison with the PTA/MgCl2
precipitation method
The results of the method comparison between homoge-
neous and precipitation-based HDL-c methods are pre-
sented in Table 6 (HDL-c range, 0.07–1.25 g/L; triglycer-
ides, #4 g/L). From the individual and pooled regression
equations, it can be seen that the homogeneous HDL-c
assay produced results that were significantly higher
(P ,0.05) than those produced with the PTA/MgCl2
assay. The same holds for laboratories 3 and 4, which
used the combined ultracentrifugation and precipitation
method.
cholesterol interference
In Fig. 2, A and C, it is illustrated that the homogeneous
HDL-c assay does not become biased in the case of
hypercholesterolemia. All specimens examined here (n 5
35) were normotriglyceridemic (triglycerides ,2 g/L),
whereas 16 specimens were hypercholesterolemic (choles-
terol .2.4 g/L). The cholesterol range tested varied be-
tween 1.63 and 3.91 g/L, whereas average and median
biases were 2.5% and 3.0%, respectively (range, 23.0% to
10.5%). In each of the 35 samples examined, the bias of the
homogeneous HDL-c method was less than 613%.
In Fig. 2, B and D, the biases of the PTA/MgCl2
Table 3. Overall imprecision data (five runs; duplicate determinations per run) for the Boehringer homogeneous HDL-c
method compared with the Boehringer PTA/MgCl2 precipitation method.
Laboratory Analyzer
Homogeneous HDL-c methoda
PNL
lot 185 597
PNL
lot 186 586
PPL neu
lot ML02 0062
PPL neu
lot ML02 2716
Lab 1 Hitachi 911 488 6 5 435 6 4 331 6 7 300 6 6
(0.95%) (0.84%) (2.26%) (2.10%)
Lab 2 Hitachi 717 486 6 7 444 6 8 332 6 6 304 6 4
(1.53%) (1.72%) (1.93%) (1.32%)
Lab 3 Hitachi 911 477 6 6 431 6 3 321 6 5 292 6 6
(1.34%) (0.70%) (1.58%) (1.96%)
Lab 4 Hitachi 911 512 6 7 463 6 4 355 6 5 322 6 7
(1.40%) (0.93%) (1.30%) (2.21%)
Lab 5 Hitachi 911 488 6 10 449 6 11 338 6 8 307 6 4
(2.06%) (2.42%) (2.42%) (1.34%)
PTA-MgCl2 method
a
Lab 1 Hitachi 911 457 6 7 418 6 6 301 6 5 268 6 4
(1.52%) (1.42%) (1.72%) (1.36%)
Lab 2 Hitachi 717 442 6 6 408 6 8 291 6 5 260 6 15
(1.28%) (2.08%) (1.55%) (5.82%)
Lab 3 Hitachi 911 482 6 28 436 6 17 318 6 21 286 6 16
(5.87%) (3.83%) (6.59%) (5.49%)
Lab 4 Hitachi 911 467 6 13 430 6 8 313 6 8 288 6 3
(2.72%) (1.78%) (2.52%) (1.20%)
Lab 5 Hitachi 911 441 6 6 417 6 8 292 6 9 264 6 9
(1.34%) (2.03%) (3.05%) (3.34%)
The data were produced in a Dutch, an Italian, and three German clinical laboratories (n 5 5) using lyophilized quality control materials.
a Mean 6 SD (mg/L) (CV, %).
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precipitation method are displayed as a function of
HDL-c and cholesterol concentration, respectively. Aver-
age and median biases were 21.9% and 22.0%, respec-
tively (range, 29.4% to 4.5%). Analogously, no bias could
be demonstrated across the cholesterol range tested.
triglyceride interference
In Fig. 3, A and C, it is illustrated that the homogeneous
HDL-c assay becomes positively biased in case of severe
hypertriglyceridemia, a condition frequently encountered in
conjunction with low HDL-c concentrations. The triglycer-
ide range tested varied between 2 and 59 g/L. In case of
triglyceride concentrations #20 g/L (n 5 78), average and
median biases were 4.3% and 3.7%, respectively (range,
226.3% to 47.2%). In all specimens with triglycerides .20
g/L, huge positive biases were demonstrated for the homo-
geneous HDL-c method, ranging between 51% and 578%. At
triglyceride concentrations #10 g/L, the bias of the homo-
geneous HDL-c method was less than 613% in 60 of 66
samples; from 10 g/L on, unacceptable triglyceride interfer-
ence could eventually appear.
In Fig. 3, B and D, the biases of the PTA/MgCl2
precipitation method are displayed as a function of
HDL-c and triglyceride concentration, respectively. Over-
all, a tendency to an increasingly negative bias with
increasing triglyceride concentrations existed, especially
.10 g/L of triglycerides. If triglycerides were #20 g/L
(n 5 78), average and median biases were 27.3% and
Table 4. Interlaboratory survey (five runs; duplicate determinations per run) of the Boehringer homogeneous HDL-c method
and the Boehringer PTA/MgCl2 precipitation method in five clinical laboratories using frozen human serum samples.
Laboratory Analyzer
Homogeneous HDL-c methoda
HS1 HS2 HDL-c 114AEJ 4.96
Lab 1 Hitachi 911 644 6 15 364 6 10 504 6 6
(2.40%) (2.63%) (1.10%)
Lab 2 Hitachi 717 663 6 11 381 6 10 519 6 5
(1.72%) (2.63%) (1.00%)
Lab 3 Hitachi 911 648 6 13 363 6 10 508 6 10
(1.98%) (2.66%) (1.91%)
Lab 4 Hitachi 911 703 6 11 413 6 7 561 6 8
(1.60%) (1.59%) (1.47%)
Lab 5 Hitachi 911 660 6 12 373 6 9 514 6 8
(1.76%) (2.44%) (1.60%)
PTA-MgCl2 method
a
Lab 1 Hitachi 911 626 6 4 348 6 3 473 6 6
(0.58%) (0.80%) (1.32%)
Lab 2 Hitachi 717 622 6 6 351 6 21 470 6 8
(1.04%) (6.06%) (1.77%)
Lab 3 Hitachi 911 666 6 23 376 6 16 489 6 28
(3.43%) (4.13%) (5.74%)
Lab 4 Hitachi 911 695 6 32 408 6 17 502 6 11
(4.55%) (4.18%) (2.27%)
Lab 5 Hitachi 911 606 6 12 324 6 8 459 6 7
(2.03%) (2.50%) (1.48%)
a Mean 6 SD (mg/L) (CV, %).
Table 5. Reference standardization of field HDL-c methods.
CRMLNa
laboratory Y method X method n Slope (95% CI)
Intercept (95% CI),
mg/L
Correlation
coefficient
Mean X,
mg/L
Mean Y,
mg/L
Rotterdam Homogeneous HDL-c Reference Method 41 1.068b (1.018–1.105) 217 (233–15) 0.993 501 514
Rotterdam PTA/MgCl2 Reference Method 41 1.053
b (1.012–1.092) 241b (261–221) 0.988 501 487
Milan Homogeneous HDL-c DCMc 79 1.020b (1.000–1.042) 14b (15–124) 0.996 489 511
Milan Homogeneous HDL-c DCMd 63 1.037b (1.010–1.065) 4 (210–118) 0.996 519 541
Milan PTA/MgCl2 DCM
c 98 1.002 (0.989–1.017) 217b (226–213) 0.996 509 489
Regression analyses were done according to Passing and Bablok (19).
a CRMLN, Cholesterol Reference Method Laboratory Network; CI, confidence interval.
b Slope and/or intercept are significantly different from, respectively, one and zero at a 5 0.05.
c Includes sera with triglycerides between 2 and 4 g/L.
d Includes only sera with triglycerides #2 g/L.
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27.5%, respectively (range, 231.1% to 8.5%). In the case
of triglycerides .30 g/L (n 5 4), it was no longer possible
to get a clear and homogeneous supernatant after precip-
itation of apolipoprotein B-containing lipoproteins, not
even after making a twofold sample predilution with
physiological saline solution. Of the 81 remaining samples
in which a chemical precipitation was performed, five
samples demanded predilution to get a clear supernatant.
Discussion
Working with manufacturers is an effective means, with
great impact, for standardizing clinical analytes within
the clinical laboratory community. To this end, the Cho-
lesterol Reference Method Laboratory Network of the
CDC implemented in 1994 a program for manufacturers
to evaluate the accuracy of (HDL)-cholesterol methods
(14, 16). The program is based on the analysis of fresh
patient samples with both field and Reference Methods,
because the traditional approach of using processed ma-
terials for evaluation of accuracy is inherently flawed due
to matrix effects that cause processed materials to assay
differently from patient samples on some instrument
systems. Aims of this study were to assess the accuracy of
the newly developed homogeneous HDL-c method from
Boehringer in both normo- and dyslipidemic sera and to
compare its analytical performance and its robustness to
that of a PTA/MgCl2 precipitation method.
In 1995, the NCEP Working Group on Lipoprotein
Measurement issued performance guidelines for HDL-c
measurements that clinical laboratories should achieve by
1998 (14). In the case of HDL-c, the percentage of total
error of routine HDL-c determinations should be reduced
Fig. 1. Reference standardization study.
Percentage of bias of fresh, native, normo- and moderately hypertriglyceridemic sera as measured with the homogeneous HDL-c assay (A and C) and the PTA/MgCl2
precipitation assay (B and D) vs the HDL-c Reference Methods. The dotted line represents the mean percentage of bias of the field HDL-c methods (A, 2.2%; B, 23.9%;
C, 4.5%; D, 25.0%); the full lines represent the maximum bias related to the 1998 NCEP total error goal of 613% for singlicate HDL-c measurements.
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Fig. 2. Cholesterol interference study.
Percentage of bias of fresh, native, normo- and hypercholesterolemic sera as measured with the homogeneous HDL-c assay (A and C) and the PTA/MgCl2 precipitation
assay (B and D) vs the HDL-c Designated Comparison Method in relation to HDL-c and cholesterol concentrations, respectively. All sera were normotriglyceridemic
(triglycerides ,2 g/L). The dotted line represents the mean percentage of bias of the field HDL-c methods for all specimens evaluated (n 5 35); the full lines represent
the maximum bias related to the 1998 NCEP total error goal of 613% for singlicate HDL-c measurements.
Table 6. Summary of field method comparisons.
Lab Y method X method n Slope (95% CI)a
Intercept (95% CI),
mg/L
Correlation
coefficient
Mean X,
mg/L
Mean Y,
mg/L
Homogeneous HDL-c PTA/MgCl2 [CFAS]
b
1 99 1.021 (0.998–1.047) 12c (3–21) 0.994 429 451
2 79 1.016 (0.991–1.047) 36c (22–49) 0.992 466 510
3 100 1.024 (0.990–1.060) 4 (213–22) 0.988 511 528
4 100 1.095 (1.069–1.124) 28 (219–7) 0.992 422 453
5 100 1.018 (0.980–1.057) 39c (20–56) 0.985 508 557
Overall 478 1.037c (1.022–1.052) 15c (7–22) 0.987 468 499
Homogeneous HDL-c UC 1 PTA/MgCl2 [CFAS]
3 and 4 200 1.059c (1.034–1.082) 12c (3–21) 0.986 451 490
Regression analyses were done according to Passing and Bablok (19) if n # 200 and using orthogonal regression if n . 200.
a CI, confidence interval.
b PTA/MgCl2 [CFAS]: PTA/MgCl2 assay standardized with CFAS.
c Slope and/or intercept are significantly different from, respectively, one and zero at a 5 0.05.
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to #13%. Per definition, total error can be interpreted as
an error budget one can divide between analytical impre-
cision (CVa) and average bias. One set of conditions that is
consistent with the total error goal is that at an HDL-c
concentration of $0.42 g/L the CVa should be #4% and
the average bias less than or equal to 65%.
In this study, it is illustrated that the homogeneous
HDL-c assay, applied on Hitachi type analyzers, has an
excellent reproducibility; total CVs ranged between 1.88%
and 3.08% and were similar among different reagent lots
(Table 2). From the field method comparison study, it
became obvious that total CVs of the PTA/MgCl2 assay
differed substantially among laboratories in both lyophi-
lized and frozen control materials (Tables 3 and 4). For
example, CVs ranged between 1.36% and 6.59% in pro-
cessed controls and between 0.58% and 6.60% in frozen sera,
signifying that not all laboratories that use the PTA/MgCl2
assay are able to reach the 1998 imprecision goal (14). In
contrast, total CVs of the homogeneous HDL-c method
were less by one-half and much more consistent among
participating centers, ranging between 0.70% and 2.26% in
lyophilized controls and between 1.00% and 2.66% in
fresh frozen sera. From the precision data, it is evident
that the precision of the homogeneous HDL-c assay
amply meets the 1998 NCEP requirements. In addition,
the random error of the homogeneous HDL-c assay
fulfills the generally accepted criterion for usefulness of a
medical test, stating that the CVa should be no greater
than one-half the average biological variation (the biolog-
ical CV of HDL-c is usually considered to be 7.5%) (14).
Fig. 3. Triglyceride interference study.
Percentage of bias of fresh, native, hypertriglyceridemic sera as measured with the homogeneous HDL-c assay (A and C) and the PTA/MgCl2 precipitation assay (B and
D) vs the HDL-c Reference Method in relation to HDL-c and triglyceride concentrations, respectively. The dotted line represents the mean percentage of bias of the field
HDL-c methods for all specimens evaluated (homogeneous method, n 5 85; PTA/MgCl2 method, n 5 81); the full lines represent the maximum bias related to the
1998 NCEP total error goal of 613% for singlicate HDL-c measurements.
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The bias survey in normo- and moderately hypertri-
glyceridemic sera displayed a positive mean bias of
similar magnitude in either CDC Network Laboratory
(Table 5; Fig. 1, A and C). Notwithstanding the presence
of a significant positive bias, the homogeneous assay met
the 1998 total error goal, suggesting acceptable calibration
of the method and adequate specificity for HDL, at least in
normo- and moderately hypertriglyceridemic specimens.
Analogously, results of the field method comparison
(Table 6) demonstrated a positive bias of the homoge-
neous HDL-c assay compared with the PTA/MgCl2 assay.
The systematic difference is explained, first, by the arbi-
trary initial value setting of the homogeneous HDL-c
calibrator, and second, because the CFAS calibrator of the
PTA/MgCl2 assay is value assigned by the Definitive
Method, which produces results that are approximately
1.5% lower compared with those produced with the
Reference Method (16).
As CDC Network Laboratories strive to assist manu-
facturers in documenting and improving their method
accuracy (14, 16), a calibrator reassignment was recom-
mended for the homogeneous assay. Accordingly, Boehr-
inger Mannheim adjusted the calibrator value to 97% of
its preliminary target value. Assuming a maximum CVa of
3.08% (Table 2), the calibrator reassignment implies that
total error of future homogeneous HDL-c measurements
will be about 5.2% to 7.5% instead of 8.2% to 10.5%.
By means of the reference standardization part of the
study, traceability of the Boehringer homogeneous HDL-c
assay to the CDC Reference Methods has been estab-
lished. Of course, the results presented here only apply to
the specific analytical system evaluated (instrument
model, reagent lot, and calibrator lot) and do not guaran-
tee accuracy of future reagent and calibrator lots. Not-
withstanding, conventional in-house quality control pro-
cedures at the manufacturer’s site should be adequate to
monitor the system in the future. If shifts are observed or
suspected, another direct comparison with the HDL-c
Reference Methods should be undertaken to reset the
system for optimal accuracy.
The comparative bias surveys of conventional and
direct HDL-c assays using fresh, dyslipidemic sera illus-
trate that the new Boehringer homogeneous HDL-c assay
is as robust as the PTA/MgCl2 precipitation method up to
at least 3.91 g/L serum cholesterol (Fig. 2) and up to 10
g/L of serum triglycerides (Fig. 3). Above 10 g/L of
serum triglycerides, the homogeneous HDL-c assay suf-
fers from serious nonspecificity, leading to overestimation
of the HDL-c concentration, whereas the PTA/MgCl2
precipitation method becomes increasingly negatively bi-
ased. The observed percentage of bias largely varied
among individuals having similar triglyceride concentra-
tions and likely illustrates an effect of lipoprotein compo-
sition (Fig. 3, C and D). Whether sample predilution or the
use of a reduced sample volume (3 mL in stead of 4 mL)
could reduce bias in grossly dyslipidemic sera by using
the Boehringer homogeneous HDL-c assay warrants fur-
ther investigation.
We conclude that the new homogeneous HDL-c assay
amply meets the 1998 NCEP recommendations for total
error; its precision is superior compared with the PTA/
MgCl2 precipitation method, and its average bias remains
well below 5% in case of moderate, isolated hypercholes-
terolemia or as long as serum triglyceride concentrations
are #10 g/L.
We thank all technical assistants of the participating
laboratories who were involved in this study for doing the
analytical work. We also thank Boehringer Mannheim,
Germany, for providing test kits free of charge.
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